Technology innovation companies show their skills in testing products at the forefront of epidemic

category:Finance
 Technology innovation companies show their skills in testing products at the forefront of epidemic


On January 28, in the second batch of kits approved by the State Food and drug administration, Shengxiang biology adopted the original RNA one-step technology with a sensitivity of 200 copies / ml. sample processing and amplification detection can be completed in a PCR reaction tube, minimizing the risk of biosafety and cross contamination, and the results can be given in 30 minutes. According to Luo Zhaofeng, this almost reaches the detection time limit of this method.

As the gathering place of Chinas scientific and technological enterprises, scientific and technological innovation board also has a number of testing reagent companies that have announced the research and development of testing reagent products for new coronavirus. In response to the epidemic situation caused by the new coronavirus in Wuhan, shuoshi biology developed a new coronavirus nucleic acid detection kit and a general-purpose coronavirus nucleic acid detection kit based on the technology of fluorescence PCR. On January 27, shuoshi biology, together with meinian university health, donated 46000 new coronavirus nucleic acid detection reagents and instruments to Wuhan Red Cross Society and Hubei Charity Federation.

Hot view biology also issued a notice. Based on the fluorescence quantitative PCR technology, the company completed the development of a new coronavirus nucleic acid detection kit (PCR fluorescence probe method) on January 20. The above products are only used for the detection of new coronavirus, not for treatment, and only for scientific research products, without obtaining product registration certificate. In the face of the epidemic situation, thermocline provided 1000 boxes of new coronavirus nucleic acid detection reagents to clinical medical institutions for emergency free, providing guarantee for the epidemic prevention and control of clinical medical institutions. In order to better prevent and control the epidemic situation, thermobiology started the research and development of immunoassay reagent which can detect new coronavirus in 15 minutes.

Chen Hongyan, Secretary General of the medical equipment branch of China Medical Materials Association, told the Securities Daily: for this new coronavirus infection of pneumonia, the launch speed of the test kit is gratifying, which is very conducive to the hospitals rapid identification of the infected population. The largest number of patients in the hospital are suspected cases, which need to be further tested to distinguish whether they are infected with the virus. While waiting for the test results, there will be a cross infection problem. The faster the test, the lower the probability of infection.

Chen Hongyan said that many biological medical companies can quickly develop the detection reagents after the publication of the new coronavirus gene sequence, and achieve high detection accuracy and short detection time, which fully demonstrates the advanced technology and localization results of the in vitro diagnostic industry in China. In recent years, the road of independent research and development by Chinese enterprises has not gone away, and the important work has been displayed at the critical moment. Use.

A biomedical investment banker told reporters that the outbreak is a severe challenge for the diagnostic reagent industry. At present, the results are remarkable, and the supply of diagnostic reagents is increasingly sufficient. But it also exposed a problem, that is, the diagnostic reagents need to pass the centralized test in the laboratory, which has the problems of long test time and exposure to infection. POCT (on-site timely detection) products are not put in the first place in this epidemic, only a few companies have product research. Wanfu biological donated about 30 million yuan of POCT medical materials to fever clinics and designated hospitals in each province on January 30 after developing multiple nucleic acid detection cards for new coronavirus respiratory pathogens, new coronavirus detection reagents and other products, and built 200 1-m-square meter POCT accompanying rapid examination rooms. It is reported that the POCT can produce test results in 15 minutes with the rapid examination room as soon as possible, which can form targeted solutions for CDC, medical institutions, community and grass-roots medical scenes, and meet the medical needs of fever clinics and negative pressure laboratories in all provinces. Source: responsible editor of Securities Daily: Yang qian_nf4425

A biomedical investment banker told reporters that the outbreak is a severe challenge for the diagnostic reagent industry. At present, the results are remarkable, and the supply of diagnostic reagents is increasingly sufficient. But it also exposed a problem, that is, the diagnostic reagents need to pass the centralized test in the laboratory, which has the problems of long test time and exposure to infection. POCT (on-site timely detection) products are not put in the first place in this epidemic, only a few companies have product research.

Wanfu biological donated about 30 million yuan of POCT medical materials to fever clinics and designated hospitals in each province on January 30 after developing multiple nucleic acid detection cards for new coronavirus respiratory pathogens, new coronavirus detection reagents and other products, and built 200 1-m-square meter POCT accompanying rapid examination rooms. It is reported that the POCT can produce test results in 15 minutes with the rapid examination room as soon as possible, which can form targeted solutions for CDC, medical institutions, community and grass-roots medical scenes, and meet the medical needs of fever clinics and negative pressure laboratories in all provinces.